| Description |
1 online resource : illustrations |
| Series |
SAGE Knowledge. Cases |
|
SAGE Knowledge. Cases
|
| Summary |
Influenced by the preliminary results of an internal clinical trial, Raymond Gilmartin, CEO of Merck, announced that the company was pulling its blockbuster arthritis drug Vioxx® from the worldwide market on September 30, 2004. Merck & Company, Inc., once the worlds largest pharmaceutical company, saw its stock price plummet 27% after the recall announcement. Facing recent sales declines, a barrage of lawsuits, and two separate government investigations, Merck is losing its once-stellar reputation in the pharmaceutical industry |
| Notes |
Originally published: Gust, A. M., Bartucci, G. D., & ORourke, J. S. (2005). Merck & Company, Inc.: The recall of Vioxx® (A). 05-01 (A). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame |
|
Description based on XML content |
| Subject |
Merck & Co.
|
| SUBJECT |
Merck & Co. fast |
| Subject |
Pharmaceutical industry -- Public relations
|
|
Product recall.
|
|
Antiarthritic agents -- Testing
|
|
Antiarthritic agents -- Testing
|
|
Pharmaceutical industry -- Public relations
|
|
Product recall
|
| Genre/Form |
Case studies.
|
|
Études de cas.
|
| Form |
Electronic book
|
| Author |
Bartucci, Grant D., author
|
|
O'Rourke, James S., 1946- author.
|
| ISBN |
9781526406385 |
|
1526406381 |
|
